These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8460017)

  • 1. [Serologic monitoring of patients with endometrial carcinoma using ovarian carcinoma antigen (CA 125)].
    Göcze P; Varhson H
    Orv Hetil; 1993 Mar; 134(13):685-8. PubMed ID: 8460017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of determination of squamous cell carcinoma antigen in the follow up of patients with cancer of the uterine cervix].
    Göcze P; Vahrson H
    Orv Hetil; 1992 Dec; 133(50):3191-4. PubMed ID: 1461640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of CA-125 antigen in the monitoring of therapy and clinical course of ovarian cancer].
    Pulay T; Csömör S
    Orv Hetil; 1987 Dec; 128(50):2615-9. PubMed ID: 3323994
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H; Tatra G; Bieglmayer C
    Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
    Bast RC; Klug TL; St John E; Jenison E; Niloff JM; Lazarus H; Berkowitz RS; Leavitt T; Griffiths CT; Parker L; Zurawski VR; Knapp RC
    N Engl J Med; 1983 Oct; 309(15):883-7. PubMed ID: 6310399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 125 for the monitoring of ovarian carcinoma during primary therapy.
    Lavin PT; Knapp RC; Malkasian G; Whitney CW; Berek JC; Bast RC
    Obstet Gynecol; 1987 Feb; 69(2):223-7. PubMed ID: 2433652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor antigens CA 125 and CA l9-9 in the serum of patients with gynecologic trophoblastic tumors and colorectal carcinoma].
    Göcze P; Szabó D; Than G; Csaba I; Krommer K
    Orv Hetil; 1986 Aug; 127(35):2123-6. PubMed ID: 3024089
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
    Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
    Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
    Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
    Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.